SPPI Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 2.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Spectrum Pharmaceuticals Insider Trading History Chart
This chart shows the insider buying and selling history at Spectrum Pharmaceuticals by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Spectrum Pharmaceuticals Share Price & Price History
Current Price: $1.03
Price Change: +0.30 (1.20%)
As of 08/1/2023 01:00 AM ET
Spectrum Pharmaceuticals Insider Trading History
Spectrum Pharmaceuticals Institutional Trading History
Data available starting January 2016
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.
Read More on Spectrum Pharmaceuticals
Volume
N/A
Average Volume
1,927,028 shs
Market Capitalization
$211.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.15
Who are the company insiders with the largest holdings of Spectrum Pharmaceuticals?